249 related articles for article (PubMed ID: 16087270)
1. Activation of dendritic cells by local ablation of hepatocellular carcinoma.
Ali MY; Grimm CF; Ritter M; Mohr L; Allgaier HP; Weth R; Bocher WO; Endrulat K; Blum HE; Geissler M
J Hepatol; 2005 Nov; 43(5):817-22. PubMed ID: 16087270
[TBL] [Abstract][Full Text] [Related]
2. Patient-derived dendritic cells transduced with an a-fetoprotein-encoding adenovirus and co-cultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells.
González-Carmona MA; Märten A; Hoffmann P; Schneider C; Sievers E; Schmidt-Wolf IG; Sauerbruch T; Caselmann WH
Liver Int; 2006 Apr; 26(3):369-79. PubMed ID: 16584401
[TBL] [Abstract][Full Text] [Related]
3. Increased immunostimulatory activity conferred to antigen-presenting cells by exposure to antigen extract from hepatocellular carcinoma after radiofrequency thermal ablation.
Zerbini A; Pilli M; Fagnoni F; Pelosi G; Pizzi MG; Schivazappa S; Laccabue D; Cavallo C; Schianchi C; Ferrari C; Missale G
J Immunother; 2008 Apr; 31(3):271-82. PubMed ID: 18317360
[TBL] [Abstract][Full Text] [Related]
4. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
[TBL] [Abstract][Full Text] [Related]
5. Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets.
Beckebaum S; Zhang X; Chen X; Yu Z; Frilling A; Dworacki G; Grosse-Wilde H; Broelsch CE; Gerken G; Cicinnati VR
Clin Cancer Res; 2004 Nov; 10(21):7260-9. PubMed ID: 15534100
[TBL] [Abstract][Full Text] [Related]
6. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses.
Zerbini A; Pilli M; Penna A; Pelosi G; Schianchi C; Molinari A; Schivazappa S; Zibera C; Fagnoni FF; Ferrari C; Missale G
Cancer Res; 2006 Jan; 66(2):1139-46. PubMed ID: 16424051
[TBL] [Abstract][Full Text] [Related]
7. [Clinical effects of dendritic cells pulsed with autologous hepatoma cell lysates on the postoperative recurrence and metastasis of hepatocellular carcinoma].
Gao J; Chen M; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2005 Jun; 13(6):432-5. PubMed ID: 15975277
[TBL] [Abstract][Full Text] [Related]
8. Immunoregulation of dendritic and T cells by alpha-fetoprotein in patients with hepatocellular carcinoma.
Ritter M; Ali MY; Grimm CF; Weth R; Mohr L; Bocher WO; Endrulat K; Wedemeyer H; Blum HE; Geissler M
J Hepatol; 2004 Dec; 41(6):999-1007. PubMed ID: 15582134
[TBL] [Abstract][Full Text] [Related]
9. Induction of specific cytolytic T lymphocytes using fusions of hepatocellular carcinoma (HCC) patient-derived dendritic cells and allogeneic HCC cell line.
Yin XY; Wang L; Lu MD; Li BJ; Huang JF
Hepatogastroenterology; 2008; 55(81):155-9. PubMed ID: 18507097
[TBL] [Abstract][Full Text] [Related]
10. Immunobiology and gene-based immunotherapy of hepatocellular carcinoma.
Geissler M; Mohr L; Ali MY; Grimm CF; Ritter M; Blum HE
Z Gastroenterol; 2003 Nov; 41(11):1101-10. PubMed ID: 14648380
[TBL] [Abstract][Full Text] [Related]
11. Specific antihepatocellular carcinoma T cells generated by dendritic cells pulsed with hepatocellular carcinoma cell line HepG2 total RNA.
Zhang L; Zhang H; Liu W; Wang H; Jia J; Si X; Ren J
Cell Immunol; 2005 Nov; 238(1):61-6. PubMed ID: 16472793
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral neoadjuvant immunotherapy using IL-12 and dendritic cells is an effective strategy to control recurrence of murine hepatocellular carcinoma in immunosuppressed mice.
Kayashima H; Toshima T; Okano S; Taketomi A; Harada N; Yamashita Y; Tomita Y; Shirabe K; Maehara Y
J Immunol; 2010 Jul; 185(1):698-708. PubMed ID: 20498356
[TBL] [Abstract][Full Text] [Related]
13. Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: Assessment of efficacy at explant analysis and of safety for tumor recurrence.
Pompili M; Mirante VG; Rondinara G; Fassati LR; Piscaglia F; Agnes S; Covino M; Ravaioli M; Fagiuoli S; Gasbarrini G; Rapaccini GL
Liver Transpl; 2005 Sep; 11(9):1117-26. PubMed ID: 16123960
[TBL] [Abstract][Full Text] [Related]
14. [Short-term curative efficacy of cytokine-induced killer cells combined micro-invasive treatments on hepatocellular carcinoma].
Zhou QM; Wu PH; Zhao M; Wang QJ; Huang LX; Li YQ; Chen SP; Xia JC
Ai Zheng; 2006 Nov; 25(11):1414-8. PubMed ID: 17094912
[TBL] [Abstract][Full Text] [Related]
15. Potential therapeutic value of dendritic cells loaded with NY‑ESO‑1 protein for the immunotherapy of advanced hepatocellular carcinoma.
Chen Y; Huang A; Gao M; Yan Y; Zhang W
Int J Mol Med; 2013 Dec; 32(6):1366-72. PubMed ID: 24085111
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of DC fused with tumor cells or transfected with tumor total RNA as potential cancer vaccines against hepatocellular carcinoma.
Zhang HM; Zhang LW; Liu WC; Cheng J; Si XM; Ren J
Cytotherapy; 2006; 8(6):580-8. PubMed ID: 17148035
[TBL] [Abstract][Full Text] [Related]
17. Induction of alpha-fetoprotein-specific CD4- and CD8-mediated T-cell response using RNA-transfected dendritic cells.
Zhang HM; Zhang LW; Ren J; Fan L; Si XM; Liu WC
Cell Immunol; 2006 Feb; 239(2):144-50. PubMed ID: 16814271
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cell as therapeutic vaccines against tumors and its role in therapy for hepatocellular carcinoma.
Sun K; Wang L; Zhang Y
Cell Mol Immunol; 2006 Jun; 3(3):197-203. PubMed ID: 16893500
[TBL] [Abstract][Full Text] [Related]
19. CD34+-derived CD11c+ + + BDCA-1+ + CD123+ + DC: expansion of a phenotypically undescribed myeloid DC1 population for use in adoptive immunotherapy.
Ward KA; Stewart LA; Schwarer AP
Cytotherapy; 2006; 8(2):130-40. PubMed ID: 16698686
[TBL] [Abstract][Full Text] [Related]
20. Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy.
Ohira M; Ohdan H; Mitsuta H; Ishiyama K; Tanaka Y; Igarashi Y; Asahara T
Transplantation; 2006 Dec; 82(12):1712-9. PubMed ID: 17198265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
